Imunon says Phase 3 OVATION 3 ovarian cancer trial enrollment outpaces planPUBT·17 hours agoIMNN+3.90%
EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer Studybenzinga_article·17 hours agoIMNN+3.90%
Beneath the Mega-Caps: Niche U.S. Equities Prep for H2 2026 MovesGlobal Report·Jul 26 at 04:18 AMFRGT+2.04%NPB-0.12%
The Biotech Survival Charade: Stop Buying the "AI Pivot" HypeGlobal Report·Jul 26 at 04:14 AMINM-10.18%ONCY+0.19%
Divergent Fundamentals Across US Sectors: 2026 Mid-Year Operations TrackedGlobal Report·Jul 25 at 04:13 AMPHM-2.70%REKR+2.50%
Tech's Misfit Toys: Who's Actually Building and Who's Faking It?Global Report·Jul 24 at 04:13 AMFRTT-0.69%CYCU+495.85%
IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development | IMNN Stock NewsStockTitan·Jul 23 at 12:25 AMIMNN+3.90%
The Edge of the 2026 Market: From Biotech Gambles to Desperate AI PivotsGlobal Report·Jul 22 at 04:17 AMDASH+2.07%PWR+17.26%
Imunon General Counsel Susan Eylward disposes of 2,150 common shares worth $3,830.44PUBT·Jul 21 at 03:16 PMIMNN+3.90%
Exclusive: Imunon Says Lead Drug Continues To Show Promise in Advanced Ovarian Cancer Patientsbenzinga_article·Jul 21 at 07:30 AMIMNN+3.90%
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga_article·Jul 21 at 07:05 AMZYBT+10.57%IMNN+3.90%
